On July 17, 2026, the U.S. Food and Drug Administration approved Lipfendra (enlicitide) as the first oral PCSK9 inhibitor. This approval marks a significant advancement in the management of LDL cholesterol in adults with hypercholesterolemia.
Lipfendra is intended for use as an adjunct to diet and exercise, offering a new therapeutic option for adults, including those diagnosed with heterozygous familial hypercholesterolemia. The medication broadens the tools available for cardiology and primary care professionals in lipid management.
This development reflects ongoing efforts to improve cardiovascular health outcomes by expanding treatment options for patients with elevated LDL cholesterol levels.